Aratana Therapeutics, Inc. (PETX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.30 / 7.16
Exchange NASDAQ
Div & Yield N.A. (N.A)
Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Trading Action Has Improved, Here's What I Am Playing

Trading Action Has Improved, Here's What I Am Playing

Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.

It's an Actual Pullback for a Change

It's an Actual Pullback for a Change

This morning the most notable aspect of the action is the complete failure to bounce so far.

We Hit Dow 20K, Now What?

We Hit Dow 20K, Now What?

How to play the market now that the DJIA has finally crossed 20,000.

So We Hit Dow 20K, Now What?

So We Hit Dow 20K, Now What?

Keep in mind that moves like this create underlying support.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

7 Low-Priced Stocks to Watch in 2017

7 Low-Priced Stocks to Watch in 2017

Good picks make it easier to produce good results, but they are just a starting point.

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

Aratana Therapeutics Enters Oversold Territory (PETX)

Aratana Therapeutics Enters Oversold Territory (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of PETX January 2017 Options Trading

First Week of PETX January 2017 Options Trading

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new January 2017 contracts and identified the following put contract of particular interest.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

Shark Bites: As Market Calms Down, Time to Shift Gears

Shark Bites: As Market Calms Down, Time to Shift Gears

Emotions are becoming less of an issue.

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.

Trader Be Nimble, Trader Be Quick

Trader Be Nimble, Trader Be Quick

The trading action remains quite tedious, though there are short-term opportunities out there.

In a Breakdown Like This, Focus on Preventing Further Losses

In a Breakdown Like This, Focus on Preventing Further Losses

If you control your risk, then the returns will come.

Shark Bites: Versartis Is a Biotech Worth Tracking

Shark Bites: Versartis Is a Biotech Worth Tracking

Biotechnology stocks can be risky but it's helpful to track them over time.

Disinterest and Lethargy Are Guiding This Market

Disinterest and Lethargy Are Guiding This Market

Breadth is running very poor -- at more than 2 to 1 negative.

Shark Bites: Market Responds With 'Deutsche Who?'

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Shark Bites: Big Market Move May Be in the Making -- Clear the Decks!

Shark Bites: Big Market Move May Be in the Making -- Clear the Decks!

Slew of news hasn't created much action.

Shark Bites: Not Much Reason to Buy in This Environment

Shark Bites: Not Much Reason to Buy in This Environment

I'm even staying away from the appealing stocks.

For Traders, Planning Is More Important Than the Plan

For Traders, Planning Is More Important Than the Plan

Because every stock has a unique personality that requires its own strategy.